Columbia University

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Established: 1754-01-01

Employees: 20.8K

Market Cap: -

Website: https://www.arch.columbia.edu

Clinical Trials

Discovery and Validation of Genetic Variants Affecting Microglial Activation in Alzheimer's Disease

Phase 2

Recruiting

Conditions: Alzheimer Disease

Interventions: Drug: 11C-ER176
Drug: 18F-florbetaben

First Posted Date: 2021-04-12

Last Posted Date: 2023-07-28

Lead Sponsor: Columbia University

Target Recruit Count: 250

Registration Number: NCT04840979

Locations: 🇺🇸
Columbia University Irving Medical Center, New York, New York, United States

Study of the Implementation of Telehealth-Supported LARC Provision in School-Based Health Centers

Conditions: Long Acting Reversible Contraception
Contraception Behavior

Interventions: Behavioral: Telehealth-supported LARC provision

First Posted Date: 2021-04-12

Last Posted Date: 2022-07-19

Lead Sponsor: Columbia University

Target Recruit Count: 113

Registration Number: NCT04840836

Locations: 🇺🇸
Columbia University Irving Medical Center, New York, New York, United States

Effect of Training on Brain Volume in Ataxia

Not Applicable

Completed

Conditions: Spinocerebellar Ataxias

Interventions: Behavioral: Aerobic training
Behavioral: Balance training

First Posted Date: 2021-04-08

Last Posted Date: 2022-10-12

Lead Sponsor: Columbia University

Target Recruit Count: 36

Registration Number: NCT04837027

Locations: 🇺🇸
Columbia University Irving Medical Center, New York, New York, United States

Mitochondrial Stress, Brain Imaging, and Epigenetics

Not Applicable

Completed

Conditions: Mitochondrial Diseases

Interventions: Behavioral: Trier social stress test

First Posted Date: 2021-04-05

Last Posted Date: 2024-05-06

Lead Sponsor: Columbia University

Target Recruit Count: 110

Registration Number: NCT04831424

Locations: 🇺🇸
Columbia University Irving Medical Center, New York, New York, United States

Breast Elasticity Imaging During Neoadjuvant Chemotherapy

Not Applicable

Recruiting

Conditions: Breast Cancer

Interventions: Procedure: Harmonic motion imaging

First Posted Date: 2021-04-01

Last Posted Date: 2024-05-23

Lead Sponsor: Columbia University

Target Recruit Count: 50

Registration Number: NCT04824027

Locations: 🇺🇸
Columbia University Irving Medical Center/NYP, New York, New York, United States

Smoking Cessation Pilot for People Living With HIV (PLWH)

Not Applicable

Completed

Conditions: Smoking Behaviors
Smoking Reduction
Smoking, Cigarette
HIV/AIDS
Smoking
Smoking, Tobacco
Smoking Cessation
Hiv

Interventions: Device: Lumme mobile phone application
Behavioral: Standard of Care

First Posted Date: 2021-03-22

Last Posted Date: 2023-02-23

Lead Sponsor: Columbia University

Target Recruit Count: 40

Registration Number: NCT04808609

Locations: 🇺🇸
Columbia University Irving Medical Center, New York, New York, United States

Study of Ruxolitinib in Solid Organ Transplant Recipients With Advanced Cutaneous Squamous Cell Carcinoma

Phase 2

Terminated

Conditions: Advanced Cutaneous Squamous Cell Carcinoma

Interventions: Drug: Ruxolitinib

First Posted Date: 2021-03-19

Last Posted Date: 2024-12-27

Lead Sponsor: Columbia University

Target Recruit Count: 3

Registration Number: NCT04807777

Locations: 🇺🇸
Columbia University Irving Medical Center, New York, New York, United States

Sensitivity of Frequent SARS-CoV-2 (COVID-19) Rapid Antigen Testing Regimen

Terminated

Conditions: Covid19

First Posted Date: 2021-03-18

Last Posted Date: 2021-11-18

Lead Sponsor: Columbia University

Target Recruit Count: 93

Registration Number: NCT04805840

Locations: 🇺🇸
Columbia University Irving Medical Center, New York, New York, United States

Using T-Cell Alloreactivity and Chimerism to Guide Immunosuppression Minimization in Intestinal Transplantation

Phase 1

Recruiting

Conditions: Intestinal Transplantation

Interventions: Biological: Cell Therapy

First Posted Date: 2021-03-18

Last Posted Date: 2024-03-27

Lead Sponsor: Columbia University

Target Recruit Count: 6

Registration Number: NCT04804891

Locations: 🇺🇸
Columbia University Irving Medical Center/NYP, New York, New York, United States

Romosozumab/Denosumab Study for Premenopausal IOP

Phase 2

Recruiting

Conditions: Premenopausal Idiopathic Osteoporosis

Interventions: Drug: Romosozumab Prefilled Syringe [Evenity]
Drug: Denosumab 60 MG/ML Prefilled Syringe [Prolia]

First Posted Date: 2021-03-16

Last Posted Date: 2024-02-08

Lead Sponsor: Columbia University

Target Recruit Count: 30

Registration Number: NCT04800367

Locations: 🇺🇸
Columbia University Irving Medical Center, New York, New York, United States

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy